In fiscal 2025, which ended Dec 31, 2025, United Therapeutics Corporation reported revenue of $3.2 billion, up 10.6% from the year before. Net income was $1.3 billion, a profit margin of 41.9%. Operating income came to $1.5 billion, an operating margin of 46.9%. Diluted earnings per share were $27.86. Over the twelve months ended Sep 30, 2026, revenue was $3.2 billion and net income was $1.2 billion. Across the 10 fiscal years shown, revenue grew from $1.6 billion in fiscal 2016 to $3.2 billion in fiscal 2025, about 7.9% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3,188
+1.9%
|
3,183
+10.6%
|
2,877
+23.6%
|
2,328
+20.2%
|
1,936
+14.9%
|
1,686
+13.6%
|
1,483
+2.4%
|
1,449
-11.0%
|
1,628
-5.7%
|
1,725
+7.9%
|
1,599
+9.1%
|
| Cost of revenue |
435
+22.0%
|
384
+24.1%
|
310
+20.3%
|
258
+69.9%
|
152
+23.8%
|
122
+13.3%
|
108
-8.1%
|
118
-40.8%
|
199
+88.0%
|
106
+45.4%
|
73
+5.4%
|
| Gross profit |
2,752
-0.7%
|
2,798
+9.0%
|
2,568
+24.0%
|
2,070
+16.0%
|
1,785
+14.2%
|
1,563
+13.7%
|
1,375
+3.3%
|
1,331
-6.9%
|
1,429
-11.8%
|
1,620
+6.1%
|
1,526
+9.3%
|
| Research and development |
703
+29.2%
|
550
+14.3%
|
481
+17.9%
|
408
+26.4%
|
323
-40.2%
|
540
+51.0%
|
358
-69.8%
|
1,183
+230.4%
|
358
+35.3%
|
265
+79.3%
|
148
-39.8%
|
| Selling, general and administrative |
728
-0.8%
|
756
+6.5%
|
710
+48.8%
|
477
|
—
|
—
|
—
|
—
|
266
-19.5%
|
330
+4.2%
|
317
-30.0%
|
| Operating expenses |
1,431
+12.0%
|
1,306
+9.7%
|
1,191
+34.5%
|
885
|
—
|
—
|
—
|
—
|
624
|
—
|
464
-33.4%
|
| Operating income |
1,321
-11.5%
|
1,492
+8.4%
|
1,377
+16.2%
|
1,185
+20.9%
|
980
+76.2%
|
556
-6.4%
|
594
+416.4%
|
-188
-123.3%
|
805
-1.2%
|
815
-23.2%
|
1,062
+51.9%
|
| Interest income |
150
-24.2%
|
192
-3.6%
|
199
+22.4%
|
163
+260.0%
|
45
+170.7%
|
17
-41.6%
|
29
-35.3%
|
44
+54.5%
|
29
|
—
|
—
|
| Interest expense |
12
-51.0%
|
20
-54.5%
|
43
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other non-operating income (expense) |
48
+5477.8%
|
49
+743.1%
|
6
+141.4%
|
-14
+65.2%
|
-40
-195.3%
|
42
-14.4%
|
49
+118.1%
|
23
+393.5%
|
-8
-434.8%
|
2
+309.1%
|
-1
-1200.0%
|
| Pretax income |
1,508
-9.5%
|
1,714
+11.4%
|
1,539
+20.8%
|
1,274
+34.1%
|
951
+60.1%
|
594
-7.0%
|
639
+487.2%
|
-165
-121.7%
|
759
-1.4%
|
770
-27.4%
|
1,060
+1.5%
|
| Income tax |
277
-29.8%
|
379
+10.3%
|
344
+18.8%
|
290
+29.6%
|
223
+89.1%
|
118
-4.8%
|
124
+305.1%
|
-60
-135.7%
|
170
-51.7%
|
352
+1.5%
|
346
-11.8%
|
| Net income |
1,231
-3.2%
|
1,335
+11.7%
|
1,195
+21.4%
|
985
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Basic EPS |
28.60
+0.5%
|
30.13
+14.0%
|
26.44
+25.7%
|
21.04
+31.7%
|
15.98
+50.8%
|
10.60
-9.0%
|
11.65
+587.4%
|
-2.39
-117.7%
|
13.54
+42.5%
|
9.50
-41.7%
|
16.29
+15.0%
|
| Diluted EPS |
26.52
+0.5%
|
27.86
+13.1%
|
24.64
+24.4%
|
19.81
+32.1%
|
15.00
+49.1%
|
10.06
-12.8%
|
11.54
+582.8%
|
-2.39
-117.8%
|
13.39
+43.8%
|
9.31
-39.0%
|
15.25
+19.9%
|
| Weighted average shares, basic |
43
-3.7%
|
44
-2.0%
|
45
-3.4%
|
47
+2.9%
|
46
+1.3%
|
45
+1.6%
|
44
+0.9%
|
44
+0.7%
|
44
-1.1%
|
44
+0.5%
|
44
-4.8%
|
| Weighted average shares, diluted |
46
-3.7%
|
48
-1.2%
|
48
-2.4%
|
50
+2.5%
|
48
+2.5%
|
47
+6.1%
|
45
+1.8%
|
44
-0.5%
|
44
-2.0%
|
45
-4.1%
|
47
-8.6%
|
| Other measures | |||||||||||
| Depreciation and amortization |
96
+16.4%
|
86
+18.1%
|
72
+36.3%
|
53
+3.7%
|
51
+2.8%
|
50
+0.0%
|
50
+8.7%
|
46
+27.9%
|
36
+15.8%
|
31
-1.9%
|
32
-4.0%
|
| EBITDA |
1,417
-10.1%
|
1,578
+8.9%
|
1,450
+17.1%
|
1,238
+20.1%
|
1,031
+70.2%
|
606
-5.9%
|
644
+554.1%
|
-142
-116.8%
|
841
-0.5%
|
846
-22.6%
|
1,093
+49.4%
|
| Interest coverage |
111.02x
|
76.54x
|
32.10x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
86.34%
|
87.92%
|
89.24%
|
88.94%
|
92.17%
|
92.73%
|
92.71%
|
91.88%
|
87.79%
|
93.87%
|
95.45%
|
| Operating margin |
41.45%
|
46.89%
|
47.86%
|
50.91%
|
50.60%
|
32.98%
|
40.02%
|
-12.95%
|
49.48%
|
47.23%
|
66.41%
|
| Pretax margin |
47.30%
|
53.85%
|
53.49%
|
54.75%
|
49.09%
|
35.24%
|
43.07%
|
-11.39%
|
46.62%
|
44.60%
|
66.31%
|
| Profit margin |
38.61%
|
41.94%
|
41.53%
|
42.31%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| EBITDA margin |
44.46%
|
49.58%
|
50.38%
|
53.19%
|
53.25%
|
35.94%
|
43.38%
|
-9.78%
|
51.68%
|
49.03%
|
68.38%
|
| Effective tax rate |
18.37%
|
22.12%
|
22.35%
|
22.72%
|
23.49%
|
19.89%
|
19.42%
|
—
|
22.36%
|
45.69%
|
32.68%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UTHR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Silver Spring, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1082554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.